A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs GSK 2245035 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 6 Jul 2018.
    • 18 May 2017 Planned End Date changed from 15 Jun 2018 to 6 Jul 2018.
    • 15 May 2017 Planned End Date changed from 15 Dec 2017 to 15 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top